Incyte Corporation
115.71USD
-1.2200 (-1.04%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on INCY.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 3.4B | 3.7B | 4.2B | 5.1B | 5.9B | 6.2B |
| Q1 | 733.2M | 808.7M | 880.9M | 1.1B | 1.3B | — |
| Q2 | 911.4M | 954.6M | 1.0B | 1.2B | — | — |
| Q3 | 823.3M | 919.0M | 1.1B | 1.4B | 1.5B | — |
| Q4 | 926.7M* | 1.0B* | 1.2B* | 1.5B* | 1.5B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 1.52 | 2.65 | .150 | 6.41 | 3.10 | 8.64 |
| Q1 | .170 | .100 | .750 | .800 | 1.47 | — |
| Q2 | .720 | .900 | -2.04 | 2.04 | — | — |
| Q3 | .500 | .760 | .540 | 2.11 | -3.85 | — |
| Q4 | .127* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| .890* |
| .956* |
| 1.49* |
| 1.94 |
| — |
Debt level and coverage